Triple test

Triple test is a prenatal screening procedure used to determine if a pregnancy could be at risk for certain birth defects. This test, also known as the multiple marker screening or AFP Plus, measures the levels of three specific substances in a pregnant woman's blood: Alpha-fetoprotein (AFP), Human chorionic gonadotropin (hCG), and Estriol.

Procedure

The Triple test is typically performed between the 15th and 20th weeks of pregnancy. It involves taking a blood sample from the pregnant woman, which is then sent to a laboratory for analysis. The levels of AFP, hCG, and Estriol in the blood are measured and compared to average levels for women at the same stage of pregnancy.

Interpretation

The results of the Triple test are used to calculate a risk score for certain birth defects, including Down syndrome, Trisomy 18, and neural tube defects. It's important to note that the Triple test is a screening test, not a diagnostic test. This means it can only indicate a higher risk of these conditions, not confirm them. If the test results indicate a higher risk, further diagnostic tests such as amniocentesis or chorionic villus sampling may be recommended.

Risks and Limitations

The Triple test is a non-invasive procedure with no physical risks to the mother or baby. However, it does have limitations. The test can produce false-positive results, indicating a problem when the baby is actually healthy. It can also produce false-negative results, failing to detect a problem that is present. Furthermore, the test does not screen for all birth defects, only the ones mentioned above.

See Also

• Prenatal testing
• Down syndrome
• Trisomy 18
• Neural tube defects
• Amniocentesis
• Chorionic villus sampling

Triple test Resources
Latest articles Most recent articles Ongoing trials	Wikipedia